HM
Therapeutic Areas
CervoMed Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Neflamapimod | Dementia with Lewy Bodies (DLB) | Phase 3 |
Leadership Team at CervoMed
JA
John Alam, MD
Chief Executive Officer
WE
William Elder
Chief Financial Officer and General Counsel
MW
Matthew Winton, Ph.D.
Chief Commercial and Business Officer
KB
Kelly Blackburn, MHA
Executive Vice President, Clinical Development
JB
Joshua Boger, Ph.D.
Chair Of The Board
OI
Ole Isacson, Dr Med Sci PhD
Chair of Scientific Advisory Board
LC
Lewis Cantley, PhD
Scientific Advisory Board Member